Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

@article{Holmes2008LongtermEO,
  title={Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial},
  author={Clive Holmes and Delphine Boche and David Wilkinson and Ghasem Yadegarfar and Vivienne Hopkins and Anthony Bayer and R. W. A. Jones and Roger Bullock and Seth Love and James William Neal and Elina Zotova and James A. R. Nicoll},
  journal={The Lancet},
  year={2008},
  volume={372},
  pages={216-223}
}
BACKGROUND Immunisation of patients with Alzheimer's disease with full-length amyloid-beta peptide (Abeta(42)) can clear amyloid plaques from the brain. Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes. METHODS In June, 2003, consent for long-term clinical follow-up, post-mortem neuropathological examination, or both, was sought from 80 patients (or their carers) who had entered a phase I randomised, placebo… CONTINUE READING